NCTN: Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma (ANBL0532)
Study ID: ANBL0532
NCT Number: NCT00567567
Children's Oncology Group (COG)
Submitted in collaboration with the NCTN/NCORP Data Archive
Trial Title: NCTN: Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma (ANBL0532)
Trial Description: This randomized phase III trial compares two different high-dose chemotherapy regimens followed by a stem cell transplant in treating younger patients with high-risk neuroblastoma. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments before a peripheral blood stem cell transplant helps kill any tumor cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. High-dose chemotherapy and radiation therapy are then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the high-dose chemotherapy. It is not yet known which regimen of high-dose chemotherapy is more effective for patients with high-risk neuroblastoma undergoing a peripheral blood stem cell transplant.
Clinical data presented in the following publication(s):
- PMID 31454045
Disease type(s): CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma
Clinical Dataset(s) included:
- NCT00567567-D1 (PMID 31454045): There is one dataset associated with PMID 31454045: NCT00567567-D1. SUBJECT_ID is the patient identifier and blanks or "." represent missing data or not applicable for analyses. There is one row for each patient enrolled on the study ANBL0532. The dataset contains baseline characteristics, ineligibility reasons, MYCN amplification status, induction response, adverse event, and survival data.
You are encouraged to view the PDF data dictionaries found in the "Documents" tab of the dbGaP study page, which may contain additional information regarding the data or the associated publication(s).
- Type: Interventional
- Archive: The database of Genotypes and Phenotypes (dbGaP)
